Strata Critical Medical, Inc.(SRTA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Strata Critical Medical, Inc. (SRTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRTA at 38.9/100 on a 32-signal composite quality model, placing it at rank #2,172 of 2,960 stocks — the bottom half of the AI-ranked universe. SRTA scores in the top quartile across balance sheet strength (91.3), profitability (80.0). Areas of concern include institutional flow (9.9) and free cash flow (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Strata Critical Medical, Inc. reports quarterly revenue of $72.5M, net income of $-10.5M, an operating margin of -7.5%. Top institutional holders of SRTA by reported 13-F value include Third Point, Northern Right Capital Management, L.P., BlackRock, based on the most recent SEC filings. SRTA trades on the Nasdaq exchange and files with the SEC under CIK 1779128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Strata Critical Medical, Inc. directly from SEC EDGAR.